Advertisement
Advertisement
U.S. markets open in 2 hours 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Atara Biotherapeutics, Inc. (ATRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4400+0.0600 (+1.78%)
At close: 04:00PM EDT
3.3800 -0.06 (-1.74%)
Pre-Market: 06:15AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close3.3800
Open3.3000
Bid3.3100 x 3100
Ask3.5100 x 1300
Day's Range3.1701 - 3.4550
52 Week Range2.8300 - 20.0400
Volume2,228,525
Avg. Volume2,023,787
Market Cap321.316M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-3.6450
Earnings DateAug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Atara Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Business Wire

    Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., August 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 82,756 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 98,701 shares of Atara’s common stock to two such newly hired em

  • Business Wire

    Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

    SOUTH SAN FRANCISCO, Calif., August 03, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.

  • Zacks

    Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

    Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022. Shares were down in pre-market trading.

Advertisement
Advertisement